Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
Objective Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. Methods The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Medi...
Guardado en:
Autores principales: | Bijun Fan, Xiaoming Tan, Yueyan Lou, Yu Zheng, Liyan Zhang, Xueling Wu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7ed1120a6a494c16846682beb52de200 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Mengqiu Tang, et al.
Publicado: (2021) -
Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
por: YU Xuxu, et al.
Publicado: (2021) -
A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
por: Yang H, et al.
Publicado: (2021) -
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Huanhuan Xu, et al.
Publicado: (2021) -
Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
por: Satoru Taguchi, et al.
Publicado: (2021)